

1 Supplement

2 PCR testing

3 NP swabs were inactivated by 10 minutes incubation with Lysis buffer (PrimeStore® Molecular Transport Medium
4 or Zymo DNA/RNA Shield, <https://www.zymoresearch.com/>). Total RNA was extracted using the MagNA Pure 96
5 system (ROCHE, <https://lifescience.roche.com>) or the PSS MagLEAD extractor (<http://www.pss.co.jp>), according to
6 the manufacturer's instructions. The presence of the SARS-COV-2 RNA was detected using the Seegene Allplex
7 CoV19 detection kit, according to the manufacturer's instructions
8 (http://www.seegene.com/assays/allplex_2019_ncov_assay). Briefly, the test detects three viral genes: envelop (E),
9 nucleocapsid (N) and RNA-dependent RNA polymerase (RdRp). The integrity of the extraction procedure is
10 monitored using an internal control that is inserted into the sample prior to the extraction procedure. The PCR
11 integrity is monitored using a CoV19 positive control. Following mix assembly, the samples were analyzed using
12 the Bio-Rad CFX96 thermal cycler, and its accompanying software, CFX Maestro (<https://www.bio-rad.com/>).

13 For each sample, Ct level was defined as the Ct level of the highest viral load (low Ct).

14 **Viral Copies:** Determination of the viral genome copy number in each sample was done by generating standard
15 curves for each reaction, which allows for conversion of the PCR Cq values to target copies. PCR-generated targets
16 for each reaction in the Allpex test were transcribed to RNA using the MegaScript T7 kit (www.thermofisher.com/).
17 The resulting RNA of each target was purified and its concentration was measured for each target. The number of
18 target copies in 1 ng of purified RNA was calculated based on the amplified sequence length, thereby enabling the
19 conversion from copy number to Ct values. Serial dilutions of each target amplicon were used for RT-qPCR to
20 generate the standard curve for each reaction. The Ct values were then plotted against the calculated concentration,
21 using a semi-logarithmic scale graph, and the derived regression formula was calculated. The Ct values for each
22 sample were converted to viral genome copies using the resulting formula.

23

24

25 **I-Vitro cultures:**

26 Vero E6 cells were cultured at 37°C until reaching 70% confluence. Infection was performed using samples that
27 tested positive SARS-CoV-2 in the PCR assay with Ct value <30. The culture was incubated for 1 hour at 33°C with
28 300 µl of the filtered nasopharyngeal samples (filtration is performed to prevent bacterial infection of the culture),
29 followed by addition of 5 ml 2% FCS MEM-EAGLE medium. The infected cells were cultured for 7 days and were
30 inspected visually for the onset of cytopathic effect (CPE). Upon CPE onset, supernatants were collected, and RNA
31 was extracted as described above. The viral propagation load was determined by SARS-COV-2-specific RT-qPCR,
32 as described above.

33

34

35

36

37

38

39

40

41

42

43

44

45 **Table S1: Symptoms at presentation**

Symptom	All	Ivermectin	Placebo
Fatigue	56.8	55.3	57.1
Headache	50.6	48.9	52.4
Cough	49.4	48.9	50
Fever	48.3	51.1	45.2
Myalgia	42.7	42.6	42.9
Sore throat	30.3	27.7	33.3
Loss of taste	28.1	34	21.4
Loss of smell	28.1	34	21.4
Dizziness	19.1	21.3	16.7
Chest pain	19.1	17	21.4
Asymptomatic	16.8	20	14.3
Dyspnea	15.7	19.1	11.9
Nausea	15.7	17	14.3
Abdominal pain	14.6	21.3	7.1
Diarrhea	12.3	10.6	14.3
Vomiting	4.5	2.1	7.1
Rhinorrhea	2.2	2.1	2.4
Backpain	2.2	2.1	2.4
Rash	1.1	0	2.4
Horseness	1.1	0	2.4

46

47

48

Table S2: Culture viability at 2-4- 6 days after initiating treatment

49

	Day 2	Day 4	Day 6	Total
	Positive/Tested	Positive/Tested	Positive/Tested	Positive/Tested*
				(%)
Ivermectin	2/12	1/5	0/6	3/23 (13.0%)
lacebo	8/14	5/10	1/5	14/29 (48.2%)

50

*Fisher-exact test - P value = 0.008

51

52

53

54